Aseptic Processing

Aseptic processing vs terminal sterilisation

These are not two ways of doing the same thing, and regulators do not treat them as equivalent.

Terminal sterilisation sterilises the product in its final sealed container — typically moist heat. Because every unit is processed identically at the end, sterility can be demonstrated statistically as a Sterility Assurance Level (SAL), conventionally 10⁻⁶: no more than one non-sterile unit per million.

Aseptic processing sterilises the components separately and then assembles them without recontaminating anything. There is no terminal kill step, so sterility cannot be proven the same way. It is assured by the process — environment, equipment, gowning, and human behaviour.

The regulatory consequence is direct: if a product can be terminally sterilised, regulators expect it to be. Choosing aseptic processing for a product that could withstand terminal sterilisation is a decision that must be justified, usually on stability grounds.

Why it is chosen anyway

Most modern therapeutics leave no choice. Proteins, monoclonal antibodies, vaccines, cell and gene therapies, liposomal formulations and most lyophilised products are destroyed by terminal sterilisation conditions. As the industry has shifted toward biologics, aseptic processing has gone from exception to norm.

What actually controls contamination

The single largest source of contamination in an aseptic process is people. Every element of the design exists to reduce human intervention or separate humans from the product:

• RABS (Restricted Access Barrier Systems) — physical barriers with glove ports
• Isolators — fully sealed, decontaminated with vapourised hydrogen peroxide
• Blow-Fill-Seal — container formed, filled and sealed in one continuous operation
• Robotic/gloveless filling — removes the operator from the critical zone entirely

Aseptic Process Simulation

The process is qualified by media fill: running the entire aseptic operation with sterile growth medium in place of product, then incubating every unit. Under EU GMP Annex 1 the expectation is zero contaminated units, with any positive triggering a full investigation. Media fills must reproduce the real process, including its worst-case interventions — a media fill run more carefully than routine production proves nothing.

The 2022 Annex 1 shift

The revised EU GMP Annex 1 made the Contamination Control Strategy (CCS) the organising requirement. Rather than a list of individual controls, a firm must document how its controls work together as a system, and demonstrate that it understands where its residual risk sits. This reframed contamination control from a checklist into an argument the manufacturer has to make.